The Company expects fourth quarter sepsis and related product revenue of $2.4M, representing a sequential quarterly increase of 60% compared to the third quarter of 2023. As a result of the sepsis test backorder, the Company now expects full year total sepsis and related product revenue of $7.5M, representing a decline of 10% compared to 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TTOO:
- T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates
- T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii
- T2 Biosystems options imply 67.5% move in share price post-earnings
- T2 Biosystems Announces Reverse Stock Split Effective Today
- T2 Biosystems announces reverse stock split